Month: July 2020

SAN DIEGO, July 30, 2020 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that it will report second quarter 2020 financial results after the close of U.S. financial markets on Thursday, August 6, 2020. Kura’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.The live call may be accessed by dialing (866) 278-7953 for domestic callers and (323) 347-3281 for international callers and entering the conference code: 1697775. A live webcast and archive of the call will be available online from the investor relations section of the company website at www.kuraoncology.com.About Kura OncologyKura...

Shelton, CT, July 30, 2020 (GLOBE NEWSWIRE) —HUBBELL REPORTS SECOND QUARTER 2020EARNINGS PER DILUTED SHARE OF $1.62 ANDADJUSTED EARNINGS PER DILUTED SHARE OF $1.87(1)Q2 net sales -21% (organic -21%)Q2 diluted EPS of $1.62; adjusted diluted EPS of $1.87(1)Includes restructuring and related investment ($0.09)Q2 Free Cash Flow of $178 million(3)Reinstating FY20 diluted EPS guidance of $6.00-$6.25; adjusted EPS of $7.00-$7.25(1)SHELTON, CT. (July 30, 2020) – Hubbell Incorporated (NYSE: HUBB) today reported operating results for the second quarter ended June 30, 2020.“Hubbell effectively navigated a challenging economic environment in the second quarter, delivering operating margin expansion and strong free cash flow generation despite significantly lower volumes,” said David G. Nord, Chairman and Chief Executive Officer. “We continue...

CAMBRIDGE, Mass., July 30, 2020 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present its second quarter 2020 financial results and operational highlights in a conference call on August 6, 2020 at 8 a.m. ET.To join the call:U.S. callers should dial 1-877-317-6789 and international callers should dial +1-412-317-6789, approximately five minutes before the call.All participants should ask to be connected to the Intellia Therapeutics conference call.A replay of the call will be available through the Events and Presentations page of the Investors & Media section of the company’s website at www.intelliatx.com, beginning on August 6, 2020 at 12 p.m. ET.About Intellia TherapeuticsIntellia...

TORONTO, July 30, 2020 (GLOBE NEWSWIRE) — Aleafia Health Inc.’s (TSX: AH, OTC: ALEAF) (“Aleafia Health” or the “Company”) AssureHome Delivery, the industry-leading direct-to-door medical cannabis service, has now launched same-day delivery. Previously, the service offered next-day delivery only. Highlights include:Medical cannabis orders received before noon on any business day will be shipped and delivered the same day.Available to patients in the Greater Toronto Area and surrounding communities, home to over nine million people.Offered exclusively to medical cannabis patients registered with the Company’s wholly owned subsidiary, Emblem Cannabis Corporation.Patients receive a shipment tracking number and phone call 15 minutes prior to the driver’s arrival.Further expansion planned to other major metropolitan areas including Calgary...

BOSTON, July 30, 2020 (GLOBE NEWSWIRE) — resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases, today provided a corporate update and reported financial results for the second quarter ended June 30, 2020.“We continue to work towards completion of our planned merger with Adicet Bio, which is expected to close in the second half of 2020,” said Chen Schor, Co-Founder, President and CEO of resTORbio. “We believe that the newly combined company will be well positioned to generate greater shareholder value through the continued efforts of developing and ultimately bringing to market off-the-shelf allogeneic gamma delta T cell therapies for oncology and other diseases.”Recent Corporate HighlightsEntered into...

Series  RIKV 21 0215Settlement Date  08/04/2020Total Amount Allocated (MM)  14,500All Bids Awarded At (Price / Simple interest)  99.381 / 1.150Total Number of Bids Received  18Total Amount of All Bids Received (MM)  29,600Total Number of Successful Bids  14Number of Bids Allocated in Full  14Lowest Price / Highest Simple Interest Allocated  99.381 / 1.150Highest Price / Lowest Simple Interest Allocated  99.515 / 0.900Lowest Price / Highest Simple Interest Allocated in Full  99.381 / 1.150Weighted Average of Successful Bids (Price/Simple Interest)  99.407 / 1.101Best Bid (Price / Simple Interest)  99.515 / 0.900Worst Bid (Price / Simple Interest)  99.301 / 1.300Weighted Average of All Bids Received (Price / Simple Interest)  99.377 / 1.157Percentage Partial Allocation (Approximate)  100.00...

Flokkur  RIKV 21 0215Greiðslu-og uppgjörsdagur  04.08.2020Samþykkt tilboð að nafnverði (m.kr.)  14.500Samþykkt (verð / flatir vextir)  99,381 / 1,150Fjöldi innsendra tilboða  18Upphæð móttekinna tilboða að nafnverði (m.kr.)  29.600Fjöldi samþykktra tilboða  14Fjöldi samþykktra tilboða úthlutað að fullu  14Lægsta úthlutaða verð / Hæstu úthlutuðu flötu vextir  99,381 / 1,150Hæsta úthlutaða verð / Lægstu úthlutuðu flötu vextir  99,515 / 0,900Lægsta verð / Hæstu flötu vextir úthlutaðir að fullu  99,381 / 1,150Vegið meðaltal samþykktra tilboða (verð / flatir vextir)  99,407 / 1,101Besta tilboð (verð / flatir vextir)  99,515 / 0,900Versta tilboð (verð / flatir vextir)  99,301 / 1,300Vegið meðaltal innsendra tilboða (verð / flatir vextir)  99,377 / 1,157Hlutfall samþykktra tilboða sem tekin eru að...

– Broader Indication to Include Smallpox, Monkeypox, Cowpox, and Vaccinia Complications –NEW YORK, July 30, 2020 (GLOBE NEWSWIRE) — SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that it has filed a Marketing Authorisation Application (MAA) with the European Medicines Agency (EMA) for oral tecovirimat, the same formulation that was approved by the U.S. Food and Drug Administration (FDA) in July 2018 under the name TPOXX®.  The MAA was filed under the centralized application process, which, upon approval, and will enable sales and marketing of oral tecovirimat in all EU member states, as well as Norway, Iceland, and Liechtenstein.  SIGA has filed its application for oral tecovirimat seeking a broader label indication covering...

VANCOUVER, British Columbia, July 30, 2020 (GLOBE NEWSWIRE) — CloudMD Software & Services Inc. (TSXV: DOC, OTCQB: DOCRF, Frankfurt: 6PH) (the “Company” or “CloudMD”), a telemedicine company seeking to revolutionize the delivery of healthcare to patients, is pleased to announce that the Company has been invited to participate in the Canaccord Genuity 40th Annual Global Growth Conference August 11-13th, 2020. CloudMD’s CEO, Dr. Essam Hamza, will be presenting virtually on Wednesday, August 12th at 10am ET in track 11. The Company will also be participating in one-on-one investor meetings.Dr. Essam Hamza, CEO of CloudMD commented, “With the significant changes in the healthcare sector, namely the growth in telehealth, we are looking forward to presenting CloudMD’s revolutionary healthcare delivery platform. Equally important,...

Revenue     °     91.6% increase in Q2 2020 revenue to $112.2 million     °    54.8% increase in H1 2020 revenue to $210.1 millionNet Cash from Operating Activities     °    $50.7 million in H1 2020$     °    20.2 million in Q2 2020Adjusted EBITDA     °    228.8% increase in Q2 2020 Adjusted EBITDA to $72.7 million     °    103.5% increase in H1 2020 Adjusted EBITDA to $129.0 millionLiquidation of Navios Europe II Inc.     °    $37.7 million receivables transformed into cash and steel value$92.9 million refinancing for six product tankers     °    Maturities extended through 2027Fleet Renewal:     °    Option for 4th VLCC newbuilding under bareboat charter exercised in Q2 2020Returning capital to stockholders:     °    Quarterly dividend: $0.30 per shareMONACO, July 30, 2020 (GLOBE NEWSWIRE) — Navios Maritime Acquisition Corporation...